ONCO1 is a systemically-delivered Alphamer targeting EGFR over expression on solid tumours. Injected, Alphamers will circulate throughout body searching for metastases. The specific targeting domain of the Alphamer will lead to a high density of carbohydrate presentation on the cell surface leading to inflammation, lysis and phagocytosis of diseased cells. Our technology works on the cell surface and is unaffected by EGFR driven cell signalling and escape mechanisms. As a result, we expect our agent to be active against TKI resistant and sensitive tumours.